Skip to main content

Month: May 2021

Meridian Bioscience Reports Strong Growth in Net Revenues and EPS in Second Quarter Fiscal 2021

CINCINNATI, May 07, 2021 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the second quarter ended March 31, 2021. Second Quarter 2021 Highlights (Comparison to Second Quarter Fiscal 2020):Consolidated net revenues of $85.3 million, up 49% year-over-year Life Science segment delivered net revenues of $53.3 million, up 139% year-over-year Diagnostics segment net revenues decreased 9% year-over-year to $31.9 million, up 5% from the first quarter of fiscal 2021 Signed agreement for 2nd grant from the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADxSM) initiative – $5.5 million for ramping manufacturing of Revogene® SARS-CoV-2 Assay Submitted 510(k) for Curian® Campy assay Launched first Air-Dryable sample specific Master Mix for BloodJack Kenny,...

Continue reading

O2Gold Identifies Two New Vein Systems, Updates the Works Developed and Other Results in the Otú Centro Gold Project, in Segovia, Colombia

General maps of O2Gold mining rights(A) The Otú Fault, mines, and recorded occurrences. (B) Aurora-Quintanillo target highlighted in red and other targets.Map of targetMap of the target with the main faults, tracks, and sampled points.Samples mapSamples map of the recent campaign and their gold grades, and the mineralized veins identified with their strikes measured in the field.Sampling point RO-0197The general aspect of the host rock and detail of the vein and associate alterations.TORONTO, May 07, 2021 (GLOBE NEWSWIRE) — O2Gold Inc. (“O2Gold” or the “Company”) (TSXV: OTGO) is pleased to announce the first results of its work on the properties acquired from Grupo de Bullet (the “Properties”) earlier this year (the “Acquisition”), as well as some of the Company’s...

Continue reading

Ocugen Provides Business Update and First Quarter 2021 Financial Results

Conference Call and Webcast Today at 8:30 a.m. ETCOVAXIN demonstrates 100% efficacy against severe COVID-19 disease (including hospitalization) Master File submitted for U.S. Food and Drug Administration review prior to a planned Emergency Use Authorization application for COVAXIN $100.0 million in gross proceeds raised through a registered direct offering of common stock Key talent acquired representing an instrumental step to position Ocugen for future growthMALVERN, Pa., May 07, 2021 (GLOBE NEWSWIRE) — Ocugen, Inc. (“Ocugen”) (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today reported first quarter 2021 financial results along with a general business update. “We continue our...

Continue reading

Cronos Group Reports 2021 First Quarter Results

Receives processing license for the commercial production and sale of cannabinoids using biosynthesis Announces plans to launch Spinach™ branded edibles to the Canadian adult-use market Launches transformative Lord Jones™ brand campaign entitled, “A Higher Order” Cronos Israel expands PEACE NATURALS™ brand into the pre-roll category in the Israeli medical market TORONTO, May 07, 2021 (GLOBE NEWSWIRE) — Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”), today announces its 2021 First Quarter business results. “This quarter for Cronos Group would not have been possible without the tenacious and innovative efforts put forward by every Cronos employee across our organization. In the first quarter of 2021 our results in Canada were impacted by market dynamics due to the COVID-19 pandemic and...

Continue reading

Icanic Brands Closes Acquisition of THC Engineering

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, May 07, 2021 (GLOBE NEWSWIRE) — Icanic Brands Company, Inc. (CSE: ICAN, OTCQB: ICNAF) (“Icanic Brands” or the “Company”), a multi-state brand operator in California and Nevada, is pleased to announce, further to its news releases dated December 9, 2020 and April 15, 2021, it has completed the acquisition (the “Acquisition”) of THC Engineering, LLC (“THC Engineering”) and THC Engineering Holdings, LLC (“THC Holdings”, and collectively with THC Engineering, “THC”) pursuant to the terms of a share exchange agreement dated April 7, 2021 (the “Share Exchange Agreement”) among the Company, THC and the unitholders of THC (the “THC Unitholders”). Pursuant to the terms of the Share Exchange Agreement and in consideration...

Continue reading

PFSweb Reports First Quarter 2021 Results

– Record Bookings in LiveArea, Strong Growth in PFS Establish Solid Foundation for 2021 – ALLEN, Texas, May 07, 2021 (GLOBE NEWSWIRE) — PFSweb, Inc. (NASDAQ: PFSW), a global commerce services company, is reporting results for the first quarter ended March 31, 2021. “We have carried our operational momentum into 2021 with a record bookings quarter for LiveArea and strong performance continuing in PFS,” said Mike Willoughby, CEO of PFSweb. “Our high levels of execution across both business units allowed us to drive a 16% increase in service fee revenue year-over-year. Across our organization, we have worked to optimize our resources, further develop our strong pipeline, and stay committed to meeting our clients’ evolving needs amid a dynamic retail environment. As eCommerce tailwinds persist, we expect the solid foundation...

Continue reading

REPEAT — Clean Power Acquires Remaining Interest in PowerTap to Become 100% Owner of Hydrogen Fueling Company

VANCOUVER, British Columbia and IRVINE, Calif., May 07, 2021 (GLOBE NEWSWIRE) — Clean Power Capital Corp. (NEO: MOVE)(FWB: 2K6)(OTC: MOTNF) (“Clean Power” or the “Company” or “MOVE”) is pleased to announce that it has completed the acquisition of the remaining shares in PowerTap Hydrogen Fueling Corp. (“PowerTap”) to become the sole shareholder of PowerTap. As previously announced, the Company initially invested in PowerTap on October 27, 2020 by acquiring a 90% equity interest and on February 5, 2021, the Company acquired an additional 4.5% of PowerTap. With the latest acquisition, Clean Power has increased its equity interest in PowerTap to 100%. PowerTap’s main focus is on employing its patented hydrogen production technology to build a blue hydrogen filling station network in the United States to accommodate anticipated...

Continue reading

Verrica Pharmaceuticals Reports First Quarter 2021 Financial Results

– Expanded commercial team in preparation for potential FDA approval of VP-102 for the treatment of molluscum, which has been assigned a PDUFA goal date of June 23, 2021 – – Raised approximately $30 million, before offering expenses, in an underwritten public offering – – Granted Torii Pharmaceutical Co., Ltd. an exclusive license to develop and commercialize VP-102 for molluscum and common warts in Japan; Company recognized license revenues of $12.0 million in the first quarter – WEST CHESTER, Pa., May 07, 2021 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the first quarter ended March 31, 2021. “This is a significant time for the Company as we ramp up...

Continue reading

Acasti Announces Definitive Agreement to Acquire Grace Therapeutics, Inc.

Grace provides Acasti with a pipeline of rare and orphan disease programs, including 3 clinical stage assets that have received Orphan Drug Designation from the FDA Expects lead asset to complete PK Bridging Study in early 2022, with potential to advance directly into a Phase 3 clinical safety trial for Subarachnoid Hemorrhage Combination creates a unique rare disease company with innovative drug delivery technologies, and is expected to have ~$64M in cash at closing to advance lead clinical assets LAVAL, Québec, May 07, 2021 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST) announces it has entered into a definitive agreement to acquire Grace Therapeutics, Inc. (“Grace”), a privately held emerging biopharmaceutical company focused on developing innovative drug delivery technologies...

Continue reading

Satellite Manufacturing and Launch System Market to Reach USD 54.17 Billion by 2027; Surging Investment by Government and Space Agencies to Bolster Growth, states Fortune Business Insights™

Top companies covered in satellite manufacturing and launch system market are Airbus S.A.S (The Netherlands), Arianespace (France), Boeing (The U.S.), GeoOptics (Canada), ISISPACE GROUP (The Netherlands), JSC Academician M.F. Reshetnev (Russia), Lockheed Martin Corporation (The U.S.), Maxar Technologies (The U.S.), SpaceX (The U.S.), ViaSat Inc. (The U.S.) and more players profiled Pune, India, May 07, 2021 (GLOBE NEWSWIRE) — The global satellite manufacturing and launch system market size is expected to reach USD 54.17 billion in 2027, exhibiting a CAGR of 12.45% during the forecast period, states Fortune Business Insights, in a report, titled “Satellite Manufacturing and Launch System Market Size, Share & COVID-19 Impact Analysis, By Type (Satellite Manufacturing and Satellite Launch Systems), By Application (Communication...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.